Bullish-Play Session for Syndax Pharma (SNDX); OraSure Tech (OSUR) Gets Boost on Rapid Zika Test Deal
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) stock soared to reach a new 52-week high of $18.03 in intraday trading Tuesday, finally closing at $17.13, up $2.19 (or +14.66%) with 334,968 shares traded, representing a large increase in activity versus its average volume (3m) of 74,287.
There appears to be no relevant recent information from the clinical stage biopharmaceutical company in the street that may explain this movement in the stock.
Syndax Pharmaceuticals, which focused on developing an innovative pipeline of combination therapies in multiple cancer indications, has 17.78M Shares Outstanding, Market Capitalization (intraday) of $304.61M and SNDX stock new one-year range is from $8.97 to $18.03 per share
Shares of OraSure Technologies, Inc. (Nasdaq:OSUR) climbed more than 10% in after-hours trading Tuesday as the company said that it was awarded an up to $16.6 million, six-year contract – including an initial commitment of $7.0 million – from the U.S. federal agency Biomedical Advanced Research and Development Authority (BARDA) to speed the development of its rapid Zika tests
OSUR stock closed the regular session at $7.00, up $0.01 (or +0.14%) and 580,324 of its shares changed hands during the day
OraSure Technologies, which develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices, has 55.60M Shares Outstanding, Market Capitalization (intraday) of $388.38M and OSUR stock 52-week range is between $4.39 and $7.99 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/